Scarica l'app Stockscreener
11.04
7.54%
-0.90
Dopo l'orario di chiusura:
11.26
0.22
+1.99%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$11.94
Aprire:
$12
Volume 24 ore:
1.38M
Relative Volume:
1.27
Capitalizzazione di mercato:
$557.78M
Reddito:
-
Utile/perdita netta:
$-156.39M
Rapporto P/E:
-2.9919
EPS:
-3.69
Flusso di cassa netto:
$-123.06M
1 W Prestazione:
-6.52%
1M Prestazione:
-18.22%
6M Prestazione:
-6.00%
1 anno Prestazione:
-10.46%
Intervallo 1D:
$11.03
$12.23
Intervallo di 1 settimana:
$11.03
$12.23
Portata 52W:
$7.30
$17.28
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Nome
Kalvista Pharmaceuticals Inc
Settore
Industria
Telefono
(857) 999-0075
Indirizzo
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Confronta KALV con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
11.04 | 583.04M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.61 | 105.69B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
481.07 | 61.52B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
569.17 | 60.69B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
837.28 | 50.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
318.02 | 35.25B | 4.56B | -176.77M | 225.30M | -1.7177 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-31 | Iniziato | JMP Securities | Mkt Outperform |
| 2025-01-07 | Iniziato | TD Cowen | Buy |
| 2024-12-18 | Iniziato | BofA Securities | Buy |
| 2020-06-15 | Iniziato | H.C. Wainwright | Buy |
| 2019-07-29 | Iniziato | SVB Leerink | Outperform |
| 2019-03-20 | Iniziato | Needham | Buy |
| 2018-10-30 | Iniziato | Jefferies | Buy |
| 2018-09-21 | Iniziato | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Iniziato | BTIG Research | Buy |
Mostra tutto
Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie
Heatmap analysis for KalVista Pharmaceuticals Inc. and competitorsJuly 2025 Summary & Expert Approved Trade Ideas - newser.com
How KalVista Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Momentum & Free High Return Stock Watch Alerts - newser.com
KalVista Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Fluctuations - Markets Mojo
Will a bounce in KalVista Pharmaceuticals Inc. offer an exitDay Trade & Daily Profit Focused Screening - newser.com
What drives KalVista Pharmaceuticals Inc 4XC1 stock priceMACD Histogram Signals & Rapid Portfolio Expansion - earlytimes.in
Ekterly eases most HAE attacks within 20 minutes, trial data show - Angioedema News
How sentiment analysis helps forecast KalVista Pharmaceuticals Inc.Gap Up & Low Risk Entry Point Guides - newser.com
What makes KalVista Pharmaceuticals Inc. stock attractive to growth fundsQuarterly Market Review & Fast Gain Swing Alerts - newser.com
How to track smart money flows in KalVista Pharmaceuticals Inc.July 2025 Snapshot & AI Powered Trade Plan Recommendations - newser.com
Key resistance and support levels for KalVista Pharmaceuticals Inc.Weekly Profit Analysis & Real-Time Sentiment Analysis - newser.com
What Fibonacci levels say about KalVista Pharmaceuticals Inc. reboundDay Trade & AI Enhanced Execution Alerts - newser.com
KalVista Pharmaceuticals (NASDAQ:KALV) Earns "Sell (D-)" Rating from Weiss Ratings - MarketBeat
Can KalVista Pharmaceuticals Inc. stock sustain free cash flow growthGold Moves & Low Drawdown Momentum Trade Ideas - newser.com
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
KalVista: Prophylaxis Is Shrinking The Acute HAE TAM (NASDAQ:KALV) - Seeking Alpha
KalVista Pharmaceuticals (NASDAQ:KALV) Stock Price Down 4%Should You Sell? - MarketBeat
KalVista’s oral HAE treatment shows rapid attack control in European trials - Investing.com
KalVista (KALV) Highlights Game-Changing Oral Treatment for HAE in German Study - GuruFocus
KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY - Business Wire
KalVista Pharmaceuticals Presents New Data Highlighting the Potential of EKTERLY® (sebetralstat) to Transform On-Demand Hereditary Angioedema Treatment in Europe - The Joplin Globe
KalVista Pharmaceuticals Appoints Bilal Arif as COO and Linea Aspesi as CPO - citybiz
KalVista Pharmaceuticals, Inc. Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer, Effective October 6, 2025 - MarketScreener
KalVista Pharmaceuticals Names Bilal Arif as COO, Linea Aspesi as Chief People Officer - MarketScreener
KalVista Pharmaceuticals appoints new COO and CPO - Investing.com
KalVista Pharmaceuticals appoints new COO and CPO By Investing.com - Investing.com Australia
KalVista Pharmaceuticals Appoints Bilal Arif as Chief Operating Officer and Linea Aspesi as Chief People Officer - The Globe and Mail
KalVista Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - MarketScreener
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635c4 - MarketScreener
Can momentum traders help lift KalVista Pharmaceuticals Inc.Market Risk Report & Fast Moving Stock Watchlists - newser.com
KalVista Pharmaceuticals' Interim Trial Data of Ekterly to Treat Hereditary Angioedema Shows Rapid Symptom Relief - MarketScreener
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - 富途牛牛
Tools to assess KalVista Pharmaceuticals Inc.’s risk profileWatch List & Consistent Growth Equity Picks - newser.com
Custom strategy builders for tracking KalVista Pharmaceuticals Inc.Oil Prices & Verified Technical Signals - newser.com
KalVista Pharmaceuticals Appoints Bethany Sensenig to Board - The Globe and Mail
Is KalVista Pharmaceuticals Inc. forming a bottoming base2025 Fundamental Recap & Daily Stock Momentum Reports - newser.com
Is KalVista Pharmaceuticals Inc. (4XC1) stock included in top ETFsWeekly Investment Report & Fast Moving Trade Plans - newser.com
KalVista Pharmaceuticals Appoints Bethany L. Sensenig to Board of Directors - citybiz
KalVista Pharmaceuticals Announces Appointment of Bethany L. Sensenig to Board of Directors - BioSpace
KalVista Pharmaceuticals appoints Bethany Sensenig to board of directors By Investing.com - Investing.com Nigeria
Kalvista Pharmaceuticals Inc Azioni (KALV) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Kalvista Pharmaceuticals Inc Azioni (KALV) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Sweeny Nicole | Chief Commercial Officer |
Aug 25 '25 |
Sale |
13.42 |
1,480 |
19,862 |
32,291 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Aug 25 '25 |
Sale |
13.42 |
1,954 |
26,223 |
132,052 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Aug 25 '25 |
Sale |
13.42 |
2,336 |
31,349 |
122,505 |
| Sweeny Nicole | Chief Commercial Officer |
Aug 22 '25 |
Sale |
13.22 |
1,864 |
24,647 |
28,771 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Aug 22 '25 |
Sale |
13.22 |
2,362 |
31,232 |
130,881 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Aug 22 '25 |
Sale |
13.22 |
10,940 |
144,657 |
386,858 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Aug 22 '25 |
Sale |
13.22 |
2,942 |
38,901 |
119,841 |
| Yea Christopher | CHIEF DEVELOPMENT OFFICER |
Aug 18 '25 |
Sale |
13.19 |
2,649 |
34,932 |
129,493 |
| Audhya Paul K. | CHIEF MEDICAL OFFICER |
Aug 18 '25 |
Sale |
13.19 |
2,939 |
38,757 |
116,533 |
| Palleiko Benjamin L | CHIEF EXECUTIVE OFFICER |
Aug 18 '25 |
Sale |
13.19 |
4,409 |
58,141 |
374,548 |
2.96%
0.09%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):